You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
創健科技(03860.HK)預計年度淨虧1200萬港元-1400萬港元
格隆匯 06-13 19:55

格隆匯6月13日丨創健科技(03860.HK)公吿,自2021年11月以來,集團一直在為2021年10月成立的新藥研發公司的全面運營做準備,準備工作包括租用辦公室、聘請相關人員以及組織活動和培訓。

公司另一附屬公司已獲取許可以開始開發新藥作為一項新舉措,而集團正準備繼續為該公司獲取相關許可,因此產生了一定的勞動力成本和許可獲取成本。

公司於2021年成立並持有51%權益的合營企業也一直在籌備若干新舉措,其中涉及準備工作,包括有關研究人員的培訓以及用於進行研究的實驗室和其他設施的租賃。

該合營企業一直專注於(i)褐色脂肪細胞在再生醫學(如肥胖和美容治療)中的臨牀應用;(ii)探索褐色脂肪細胞誘導技術,促進褐變成分,即篩選技術(預防肥胖和糖尿病等疾病和開發功能性食品);(iii)帕金森病治療藥物的研發(如大麻二酚和大麻二酚相關產品的開發和銷售),並探索與其他研究機構的合作機會。

集團於截至2021年9月30日止6個月錄得股東應占虧損約560萬港元,而2020年同期股東應占溢利約為440萬港元,主要由於(i)新藥開發項目產生的研究費用約為540萬港元;(ii)根據中期報吿所披露,因公司控制權變更而作出無條件強制現金要約而招致的開支約140萬港元。

根據對集團截至2022年3月31日止年度的未經審計綜合管理賬目的初步評估以及董事會目前可獲得的其他信息,預計該虧損還將持續並反映在年度截至2022年3月31日止剩餘月份。集團預計截至2022年3月31日止年度錄得股東應占虧損1200萬港元至1400萬港元,而截至2021年3月31日止年度的股東應占溢利約為650萬港元。該虧損亦主要歸因於上文及中期報吿所披露的相同原因。儘管如此,董事會認為集團的財務狀況依然強勁。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account